Literature DB >> 15654627

Mouse serum factor(s) down-modulate the CD4 and CXCR4 molecules on human T cells conferring resistance to HIV infection in NOG mice.

Md Zahidunnabi Dewan1, Kazuo Terashima, Sunjida Ahmed, Kenji Ohba, Midori Taruishi, Naoki Yamamoto.   

Abstract

Human cells have developed innate immunity, exploiting several means to block virus infection, and viruses have evolved diverse strategies to resist these. We show here that the human immunodeficiency virus 1 (HIV-1) could neither progressively infect engrafted human leukemic T cells nor repress their growth in NOG mice. However, ED-40515(-) cells infected with HIV-1 before inoculation were found to significantly delay the onset of tumor growth and increased the survival period of NOG mice. ED-40515(-) tumor cells showed resistance to HIV-1 which was apparently correlated with the down-regulation of CD4 and CXCR4 molecules in NOG mice. Serum from three different mouse strains, including NOG, retained a suppressive effect on the CD4 molecule of ED-40515(-) cells in vitro. ED-40515(-) cells obtained from mice re-expressed CD4 and CXCR4 molecules upon in vitro culture and were again successfully infected with HIV-1. These findings indicate that HIV-1 may initially successfully delay or regress tumor growth in NOG mice, but eventually fails to do so because of the evolution of HIV-resistant cells due to a rapid down-modulation of CD4 and CXCR4. Our data also demonstrated that some unknown soluble factor(s) present in mouse serum was responsible for conferring resistance to HIV infection to human T cells.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15654627     DOI: 10.1007/s00430-004-0234-1

Source DB:  PubMed          Journal:  Med Microbiol Immunol        ISSN: 0300-8584            Impact factor:   3.402


  26 in total

1.  Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy.

Authors:  D Finzi; J Blankson; J D Siliciano; J B Margolick; K Chadwick; T Pierson; K Smith; J Lisziewicz; F Lori; C Flexner; T C Quinn; R E Chaisson; E Rosenberg; B Walker; S Gange; J Gallant; R F Siliciano
Journal:  Nat Med       Date:  1999-05       Impact factor: 53.440

2.  Infection of HTLV-III/LAV in HTLV-I-carrying cells MT-2 and MT-4 and application in a plaque assay.

Authors:  S Harada; Y Koyanagi; N Yamamoto
Journal:  Science       Date:  1985-08-09       Impact factor: 47.728

3.  The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged anti-retroviral therapy.

Authors:  B Ramratnam; J E Mittler; L Zhang; D Boden; A Hurley; F Fang; C A Macken; A S Perelson; M Markowitz; D D Ho
Journal:  Nat Med       Date:  2000-01       Impact factor: 53.440

4.  Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy.

Authors:  T W Chun; L Stuyver; S B Mizell; L A Ehler; J A Mican; M Baseler; A L Lloyd; M A Nowak; A S Fauci
Journal:  Proc Natl Acad Sci U S A       Date:  1997-11-25       Impact factor: 11.205

5.  Reservoirs of human immunodeficiency virus type 1: the main obstacles to viral eradication.

Authors:  Roger J Pomerantz
Journal:  Clin Infect Dis       Date:  2001-11-21       Impact factor: 9.079

6.  NOD/SCID/gamma(c)(null) mouse: an excellent recipient mouse model for engraftment of human cells.

Authors:  Mamoru Ito; Hidefumi Hiramatsu; Kimio Kobayashi; Kazutomo Suzue; Mariko Kawahata; Kyoji Hioki; Yoshito Ueyama; Yoshio Koyanagi; Kazuo Sugamura; Kohichiro Tsuji; Toshio Heike; Tatsutoshi Nakahata
Journal:  Blood       Date:  2002-11-01       Impact factor: 22.113

Review 7.  Therapeutic targeting of human immunodeficiency virus type-1 latency: current clinical realities and future scientific possibilities.

Authors:  S T Butera
Journal:  Antiviral Res       Date:  2000-12       Impact factor: 5.970

8.  Kinetic analysis of human T-cell leukemia virus type I Tax-mediated activation of NF-kappa B.

Authors:  T Kanno; K Brown; G Franzoso; U Siebenlist
Journal:  Mol Cell Biol       Date:  1994-10       Impact factor: 4.272

9.  Constitutive phosphorylation and turnover of I kappa B alpha in human T-cell leukemia virus type I-infected and Tax-expressing T cells.

Authors:  J Lacoste; L Petropoulos; N Pépin; J Hiscott
Journal:  J Virol       Date:  1995-01       Impact factor: 5.103

10.  A cooperative interaction between NF-kappa B and Sp1 is required for HIV-1 enhancer activation.

Authors:  N D Perkins; N L Edwards; C S Duckett; A B Agranoff; R M Schmid; G J Nabel
Journal:  EMBO J       Date:  1993-09       Impact factor: 11.598

View more
  1 in total

1.  Optimization of HIV-1 Envelope DNA Vaccine Candidates within Three Different Animal Models, Guinea Pigs, Rabbits and Cynomolgus Macaques.

Authors:  Marie Borggren; Lasse Vinner; Betina Skovgaard Andresen; Berit Grevstad; Johanna Repits; Mark Melchers; Tara Laura Elvang; Rogier W Sanders; Frédéric Martinon; Nathalie Dereuddre-Bosquet; Emma Joanne Bowles; Guillaume Stewart-Jones; Priscilla Biswas; Gabriella Scarlatti; Marianne Jansson; Leo Heyndrickx; Roger Le Grand; Anders Fomsgaard
Journal:  Vaccines (Basel)       Date:  2013-07-19
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.